Kurma Partners is expanding into Germany and has chosen Munich as its location. The Paris-based venture capital firm has been financing innovative biotech and medical technology companies across Europe since 2009, now in its third fund generation.
Peter Neubeck takes over responsibility for Kurma Partners' German investment activities. Previously, Neubeck worked at Novartis, TVM Capital Life Science and the Munich AI startup Exb Labs. He says:
"Kurma Partners has been active as a VC in the biotech sector in Europe since its founding and has developed a very successful investment strategy, especially for early-stage projects. In Germany, we see many outstanding scientific research projects competing for comparatively little early-stage venture capital. It therefore makes sense for us to become more involved here."
“Excellent environment for biotechnology”
The new fund, Kurma Biofonds III, plans to invest in 12 to 15 companies across Europe, ranging from pre-seed to growth capital. Approximately 30 percent of these will be startups from academic projects.
“We find an excellent environment for biotechnology in Germany: outstanding research, tech transfer support, a reliable network of service providers even for very complex tasks, successful biotech clusters and, of course, experienced managers and employees,”
so Thierry Laugel, founder and managing partner of the company.
"We firmly believe that our investment model will fill a gap in the German private equity market and, of course, we also want to participate in conventional VC financing rounds."
